Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07134413 | QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC | not yet recruiting | Phase 2 | 77 | Guangdong Association of Clinical TrialsOTHER | 0 | Aug 21, 2025 | clinicaltrials |
| NCT07131345 | Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma | not yet recruiting | Phase 1 / Phase 2 | 55 | National Cancer Center, ChinaOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT07131501 | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07115927 | pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer(RODEO) | not yet recruiting | Phase 2 | 40 | University College, LondonOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07128693 | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07129018 | Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer | not yet recruiting | Phase 2 | 63 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07129161 | Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07107217 | Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer(Camella) | not yet recruiting | Phase 2 | 40 | Blokhin's Russian Cancer Research CenterOTHER | 0 | Aug 17, 2025 | clinicaltrials |
| NCT07128251 | A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | not yet recruiting | Phase 2 | 47 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 17, 2025 | clinicaltrials |
| NCT07128290 | PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma(PEHRICCA) | not yet recruiting | Phase 2 | 49 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07124884 | 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab(COLOSOTO) | not yet recruiting | Phase 2 | 300 | Federation Francophone de Cancerologie DigestiveOTHER | 4 | Aug 15, 2025 | clinicaltrials |
| NCT07125950 | SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 0 | Aug 14, 2025 | clinicaltrials |
| NCT07123441 | A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 300 | Sanjun CaiOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07120451 | Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker | not yet recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | not yet recruiting | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 12, 2025 | clinicaltrials |
| NCT07117305 | CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 1 / Phase 2 | 38 | Zhengzhou UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07118566 | Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases | not yet recruiting | Phase 2 | 40 | China Medical University, ChinaOTHER | 0 | Aug 12, 2025 | clinicaltrials |
| NCT07112833 | A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 2 | 36 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06196671 | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer(PTCA199-8) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Aug 7, 2025 | clinicaltrials |
| NCT07108504 | Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2025 | clinicaltrials |
| NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma(PUPA) | not yet recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06930105 | Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL | not yet recruiting | Phase 2 | 45 | Xianmin Song, MDOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT06973525 | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.(HER2-DM-NACT) | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT07103408 | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07104617 | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | not yet recruiting | Phase 1 / Phase 2 | 48 | TYK Medicines, IncINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07101627 | A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy | not yet recruiting | Phase 2 | 149 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101822 | A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER(BRAVA PENILE) | not yet recruiting | Phase 2 | 42 | Hospital Israelita Albert EinsteinOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101848 | A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER(BRAVA VULVAR) | not yet recruiting | Phase 2 | 42 | Hospital Israelita Albert EinsteinOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07025850 | Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07097948 | Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033(Adjuvant) | not yet recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07099794 | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | not yet recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07085273 | Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer | not yet recruiting | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT07095309 | Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer(NeoART-M) | not yet recruiting | Phase 2 | 120 | Metanoic Health Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07097064 | Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers(RAIPANC) | not yet recruiting | Phase 2 | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07007780 | Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC | not yet recruiting | Phase 2 | 35 | Xijing HospitalOTHER | 0 | Jul 29, 2025 | clinicaltrials |
| NCT07090707 | PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) | not yet recruiting | Phase 2 | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 32 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07092137 | Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer | not yet recruiting | Phase 2 | 116 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Jul 29, 2025 | clinicaltrials |
| NCT07063329 | Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive | not yet recruiting | Phase 1 / Phase 2 | 108 | Avistone Pharmaceutical（Ningbo）Co., LTD.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07086326 | A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC(NEOINSPIRE) | not yet recruiting | Phase 2 | 164 | Yang Fan, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07083505 | A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT07083687 | Lorlatinib in ROS1+ NSCLC With Brain Metastasis | not yet recruiting | Phase 2 | 21 | Hunan Cancer HospitalOTHER | 0 | Jul 24, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07081607 | Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. | not yet recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 0 | Jul 23, 2025 | clinicaltrials |
| NCT06951399 | Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 21, 2025source: clinicaltrials